Text of MN SF 76 (2019)
Gender dysphoria treatment and prescribed drug medical assistance coverage requirement
Legislative text is a public record. Where LegiScan supplied it, the CC BY 4.0 credit applies.
Source: LegiScan. Bill data and text from LegiScan (legiscan.com), licensed CC BY 4.0 and used in modified form. LegiScan does not endorse the Trans Data Initiative. License: CC BY 4.0(opens another site). Source page(opens another site)
As introduced
1,940 characters
1.1
A bill for an act
1.2
relating to human services; requiring medical assistance to cover medically
1.3
necessary treatment of gender dysphoria and certain prescribed drugs for treatment
1.4
of gender dysphoria; amending Minnesota Statutes 2018, section 256B.0625,
1.5
subdivision 3a, by adding a subdivision.
1.6
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
1.7
Section 1. Minnesota Statutes 2018, section 256B.0625, subdivision 3a, is amended to
1.8
read:
1.9
Subd. 3a. Sex reassignment surgery Treatment of gender dysphoria. Sex reassignment
1.10
surgery is not covered, unless medically necessary.
1.11
Sec. 2. Minnesota Statutes 2018, section 256B.0625, is amended by adding a subdivision
1.12
to read:
1.13
Subd. 13k. Treatment of gender dysphoria. Notwithstanding subdivision 13d, paragraph
1.14
(b), clause (1), the commissioner may include drugs for the treatment of gender dysphoria
1.15
within the drug formulary established under subdivision 13d if:
1.16
(1) the drug is approved for marketing by the United States Food and Drug
1.17
Administration;
1.18
(2) the dose and indication for use of the drug is recommended by a clinical guideline
1.19
or practice parameter included in the National Guideline Clearinghouse maintained by the
1.20
United States Department of Health and Human Services Agency for Healthcare Research
1.21
and Quality; and
1
Sec. 2.
19-1186
as introduced
01/02/19
REVISOR
ACS/CH
SENATE
STATE OF MINNESOTA
S.F. No. 76
NINETY-FIRST SESSION
(SENATE AUTHORS: DIBBLE and Simonson)
OFFICIAL STATUS
D-PG
DATE
Introduction and first reading
01/10/2019
Referred to Health and Human Services Finance and Policy
2.1
(3) there is not another drug or regimen available within the formulary to treat the
2.2
condition.
2
Sec. 2.
19-1186
as introduced
01/02/19
REVISOR
ACS/CH